This Article Full Text Full Text (PDF) All Versions of this Article: 40/1/333    most recent STROKEAHA.108.525683v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Toth, G. Articles by Albers, G. W. Search for Related Content PubMed PubMed Citation Articles by Toth, G. Articles by Albers, G. W. Pubmed/NCBI databases Medline Plus Health Information Stroke Related Collections Computerized tomography and Magnetic Resonance Imaging Thrombolysis

(Stroke. 2009;40:333.)
© 2009 American Heart Association, Inc.

Emerging Therapies

Use of MRI to Estimate the Therapeutic Window in Acute Stroke

Is Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch an EPITHET for Salvageable Ischemic Brain Tissue?

From the Stanford Stroke Center, Department of Neurology and Neurological Sciences, Stanford University Medical Center, Palo Alto, Calif.

Correspondence to Gregory W. Albers, MD, Stanford Stroke Center, 701 Welch Road, Suite 325, Palo Alto, CA 94305. E-mail albers@stanford.edu

Marc Fisher MD Kennedy Lees MD Section Editors:

Key Words: diffusion-weighted MRI • perfusion-weighted MRI • ischemic penumbra • EPITHET study

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
The fundamental goal of many acute stroke therapies is rapid arterial recanalization leading to reperfusion of critically hypoperfused brain tissue. Clinical benefits of this therapeutic approach require the presence of a salvageable penumbra. It is estimated that salvageable tissue is present in up to 80% of patients with stroke who present rapidly, but these capricious zones of potentially recoverable parenchyma typically disappear within the first 6 to 12 hours after symptom onset.¹ The rate of disappearance of the penumbral tissue appears to vary considerably between individuals based on a variety of physiological factors, predominantly the availability of adequate collateral circulation. How to quickly and reliably identify these fortunate patients who may have a prolonged therapeutic window has been the ultimate quest of a large volume of modern cerebrovascular neuroimaging research.

A leading approach to this challenge has been to estimate the ischemic penumbra based on the difference between the volume of tissue that exhibits a disturbance in cerebral blood flow, as assessed by perfusion-weighted MRI (PWI), and the volume of tissue that has already developed evidence of advanced ischemic injury reflected by cytotoxic edema on diffusion-weighted MRI (DWI).² The "mismatch" regions (areas of PWI abnormality that do not have corresponding DWI lesions) have been considered likely to benefit from reperfusion therapies. This hypothesis has been assessed in a variety of recent clinical trials, including DIAS, DEDAS, DIAS II, DEFUSE, and now, most recently, EPITHET.^3–7

EPITHET was a randomized, double-blind, placebo-controlled trial designed to determine whether intravenous tissue plasminogen activator, administered . . . [Full Text of this Article]